Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polymyxin monotherapy versus polymyxin + ampicillin/sulbactam for carbapenem-resistant Acinetobacter pneumonia or bloodstream infection
RBR-4ddjxh2Recruiting
- Sponsor
- Santa Casa de Misericórdia de Limeira
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ampicillin and sulbactam in Acinetobacter infection, ventilator-associated pneumonia (VAP) and bloodstream infection (BSI) (2 arms), sponsored by Santa Casa de Misericórdia de Limeira. Started Sep 2023; status: recruiting.
02
Drugs
ampicillinsulbactam
03
Conditions
Acinetobacter infectionventilator-associated pneumonia (VAP)bloodstream infection (BSI)
Beyond the preview
Go deeper on RBR-4ddjxh2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4ddjxh2.